Evaluation of Deposits on Contact Lenses Worn Daily Wear
NCT ID: NCT00725153
Last Updated: 2012-08-23
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
55 participants
INTERVENTIONAL
2008-03-31
2008-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PureVision/Acuvue 2
PureVision contact lenses worn first, with Acuvue 2 contact lenses worn second. Both products worn for 10 hours each.
Balafilcon A contact lenses (PureVision)
Commercially marketed, soft contact lenses worn bilaterally for 10 hours
Etafilcon A contact lenses (Acuvue2)
Commercially marketed, soft contact lenses worn bilaterally for 10 hours
Acuvue 2/PureVision
Acuvue 2 contact lenses worn first, with PureVision contact lenses worn second. Both products worn for 10 hours each.
Balafilcon A contact lenses (PureVision)
Commercially marketed, soft contact lenses worn bilaterally for 10 hours
Etafilcon A contact lenses (Acuvue2)
Commercially marketed, soft contact lenses worn bilaterally for 10 hours
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Balafilcon A contact lenses (PureVision)
Commercially marketed, soft contact lenses worn bilaterally for 10 hours
Etafilcon A contact lenses (Acuvue2)
Commercially marketed, soft contact lenses worn bilaterally for 10 hours
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Visual acuity correctable to 20/30 (Snellen) or better in each eye at distance with contact lenses.
* Successfully wearing hydrogel or silicone hydrogel contact lenses prior to enrollment in the study.
Exclusion Criteria
* One functional eye or a monofit lens.
* Ocular conditions such as active acute blepharitis, conjunctival infections, and iritis.
* Any slit-lamp finding score of (1) at the Screening Visit as defined in protocol.
* Use of concomitant topical ocular prescription or over-the-counter (OTC) ocular medications.
* History of seasonal allergies with significant ocular side effects which may have an adverse impact on contact lens wear.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alcon Research
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alcon Call Center for Trial Locations
Fort Worth, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MS-006
Identifier Type: -
Identifier Source: org_study_id